Harvard Bioscience* is a global developer, manufacturer and marketer of a broad range of specialized
products, primarily apparatus and scientific instruments used to advance life science research at
pharmaceutical and biotechnology companies, universities and government laboratories worldwide.
We sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various
other specialty catalogs), our websites, and through
distributors, including GE Healthcare, Thermo Fisher Scientific and VWR. We have sales and manufacturing operations
in the United States, the United Kingdom, Germany and Spain and sales facilities in France and Canada.
Our goal is to become a leading provider of tools for life science research and to increase shareholder value.
Our strategy is to have a broad range of highly specialized but relatively inexpensive products that have strong positions in niche markets within life science research:
- We believe that having a broad product line reduces the risk of being dependent on a single technology;
- We believe that having relatively inexpensive products reduces the volatility associated with expensive capital equipment;
- We believe our well established products, brands and distribution channels provide strong barriers to entry; and
- We believe focusing on niche markets reduces head-to-head competition with the major instrument companies.
Our products are typically highly specialized for particular research applications in molecular, cellular, behavioral and
physiology research. Our products are typically well-established in fairly mature markets.
Our brands are typically well-established names that convey quality, consistency and reassurance to scientists
concerned about getting the highest quality data from their research. Our brands are often leaders in their niches.
These brands include: Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, KD Scientific, Hugo Sachs
Elektronik, Scie-Plas, BTX, and Denville Scientific.
Our distribution channels are as well-established as our brands and are intended to give us broad access to
scientists across the globe.
The growth in our continuing operations has been driven by a combination of organic growth and the acquisition
of closely related product lines. The execution of this strategy has grown our revenue from continuing operations
from $11.5 million in 1997 to $88.0 million in 2008, a CAGR of 20%. We believe we can continue to implement
this strategy and achieve high levels of both growth and profitability.
Disclaimer:
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.
